Suppr超能文献

从医学毒理学咨询中的患者临床评估角度来看合成大麻素受体激动剂使用趋势的特点。

Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.

机构信息

School of Medicine, Georgetown University, Washington, DC, USA.

Department of Emergency Medicine, MedStar Washington Hospital Center, Washington, DC, USA.

出版信息

J Psychoactive Drugs. 2021 Jul-Aug;53(3):207-214. doi: 10.1080/02791072.2020.1851826. Epub 2020 Nov 23.

Abstract

Synthetic cannabinoid receptor agonists (SCRAs) are a new class of compounds with profound psychoactive effects and potential toxicity. This study characterizes patterns in SCRA abuse using qualitative interviews with individuals receiving medical toxicology consultation. Patients with suspected exposure to a new psychoactive substance were interviewed by medical toxicologists upon presentation for acute care. Investigators collected clinical and qualitative data including knowledge, attitudes, beliefs, and practices related to psychoactive substance use. Responses were categorized by identifying themes, and statistics were generated to describe patterns of use. Overall, 69% (86) of the 124 cases of novel psychoactive substance use entered into the registry were associated with exposure to SCRAs. Most patients (68.8%) had used SCRAs at least once before the presenting episode. 47.7% considered SCRAs to be very easy to obtain, and 44.2% reported paying for the substances while 32.6% acquired it for free. Nearly half (48.8%) of patients reported their primary reason for use was to get high; a small proportion used SCRAs to avoid testing positive on drug screening (6.9%) or as an alternative to marijuana (4.6%). Findings suggest an independent and stable culture is developing around the use of SCRAs separate from their appeal as an "undetectable" alternative to marijuana.

摘要

合成大麻素受体激动剂(SCRAs)是一类具有深刻精神活性作用和潜在毒性的新型化合物。本研究通过对接受医学毒理学咨询的个体进行定性访谈,描述了 SCRA 滥用的模式。在出现急性治疗时,医学毒理学家对疑似接触新型精神活性物质的患者进行访谈。调查人员收集了与精神活性物质使用相关的临床和定性数据,包括知识、态度、信念和实践。通过确定主题对回答进行分类,并生成统计数据来描述使用模式。总体而言,在进入登记册的 124 例新型精神活性物质使用案例中,有 69%(86 例)与 SCRAs 暴露有关。大多数患者(68.8%)在出现发作之前至少使用过一次 SCRAs。47.7%的人认为 SCRAs 非常容易获得,44.2%的人报告支付了这些物质的费用,而 32.6%的人免费获得了这些物质。近一半(48.8%)的患者报告他们使用的主要原因是为了获得快感;一小部分人使用 SCRAs 是为了避免药物筛查呈阳性(6.9%),或者作为大麻的替代品(4.6%)。研究结果表明,一种独立且稳定的文化正在围绕 SCRAs 的使用发展,而不是将其作为大麻的“不可检测”替代品的吸引力。

相似文献

1
Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
J Psychoactive Drugs. 2021 Jul-Aug;53(3):207-214. doi: 10.1080/02791072.2020.1851826. Epub 2020 Nov 23.
2
Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
Am J Emerg Med. 2019 Oct;37(10):1846-1849. doi: 10.1016/j.ajem.2018.12.044. Epub 2018 Dec 24.
3
Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
Int J Drug Policy. 2022 Aug;106:103756. doi: 10.1016/j.drugpo.2022.103756. Epub 2022 Jun 20.
4
Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
Psychopharmacology (Berl). 2022 May;239(5):1349-1357. doi: 10.1007/s00213-021-05945-1. Epub 2021 Sep 17.
6
[Intoxications with synthetic cannabinoids].
Ned Tijdschr Geneeskd. 2023 Mar 16;167:D7145.
7
[Intoxications with synthetic cannabinoids].
Ned Tijdschr Geneeskd. 2023 Feb 8;166:D7145.

引用本文的文献

1
From Patient Registry to Multi-Center Research Consortium: the Toxicology Investigators Consortium (ToxIC) Turns Fifteen.
J Med Toxicol. 2024 Jul 11;20(3):293-298. doi: 10.1007/s13181-024-01020-1. Epub 2024 Jun 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验